TLDR Gendered social factors, not just biology, contribute to sex differences in adverse drug events.
The study analyzed over 33 million records from the FDA Adverse Events Reporting System (FAERS) to explore sex disparities in adverse drug events (ADEs) through the Gender Hypothesis. It found that women report more ADEs than men, particularly in patient-reported cases and non-severe outcomes, while serious ADEs were more frequently reported in males. The study identifies four pathways through which gender influences ADE reporting: healthcare utilization, clinical bias, subjective experience of adverse events, and upstream social determinants of health. The findings suggest that addressing gendered social factors could help mitigate sex disparities in ADEs, highlighting the need for nuanced research designs and more precise gender/sex categories in health datasets.
4 citations,
July 2021 in “International Journal of Environmental Research and Public Health” Women who lost hair from childhood head radiation are more likely to face mental health issues than men.
8 citations,
November 2019 in “Dermatologic Clinics” AGA treatments like minoxidil and LLLLT are safe and effective for gender minority patients.
23 citations,
August 2018 in “Anais Brasileiros De Dermatologia” Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
13 citations,
June 2018 in “Current Urology Reports” Hair loss drugs may cause sexual issues and infertility in men.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
7 citations,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
69 citations,
July 2015 in “Pharmacotherapy” Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
